CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome

Muscle and Nerve

Volumn 40, Issue 1, 2009, Pages 42-49

  Petzold, A ^a   Brettschneider, J ^b   Jin, K ^c   Keir, G ^a   Murray, N M F ^a   Hirsch, N P ^a   Itoyama, Y ^c   Reilly, M M ^a   Takeda, A ^c   Tumani, H ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebrospinal fluid; Glial fibrillary acidic protein; Neurofilaments; Polyradiculopathy; Protein biomarker; S100B; Surrogate marker; Tau

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN S100B; TAU PROTEIN;

ACCURACY; ACUTE DISEASE; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED STUDY; FEMALE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NERVE INJURY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DETERMINATION;

AGED; AXONS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE GROWTH FACTORS; NEURAL CONDUCTION; NEUROFILAMENT PROTEINS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 67650234232     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21239     Document Type: Article

References (21)

1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21-24. (Pubitemid 20178648)
2. Blankenstein MA, Clark C, De Deyn PP, Galasko D, Hartmann T, Hampel H, et al. Multicenter comparison of assays for cerebrospinal fluid (CSF) markers for Alzheimer disease. Clin Chim Acta 2005;355:S175.
3. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Radiology 2003;226:24-28. (Pubitemid 36163903)
4. Green AJE, Keir G, Thompson EJ. A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods 1997;205:35-41. (Pubitemid 27297832)
5. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-788. (Pubitemid 28516049)
6. Hiraga A, Kuwabara S. Early prediction of prognosis in Guillain-Barre syndrome. Lancet Neurol 2003;6:572-573.
7. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:326-332.
8. Jin K, Takeda A, Shiga Y, Sato S, Ohnuma A, Nomura H, et al. CSF tau protein: a new prognostic marker for Guillain-Barre syndrome. Neurology 2006;67:1470-1472. (Pubitemid 44632077)
9. Leger JM, Bolgert F. Simple scoring system to predict outcome in Guillain-Barre syndrome. Nat Clin Pract Neurol 2007;3:658-659.
10. Nguyen QT, Sanes JR, Lichtman JW. Pre-existing pathways promote precise projection patterns. Nat Neurosci 2002;5:861-1807 (Pubitemid 34976651)
11. Petzold A, Hinds N, Murray NM, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barre syndrome. Neurology 2006;67:1071-1073. (Pubitemid 44454609)
12. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004;287:169-177. (Pubitemid 38510218)
13. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190. (Pubitemid 37281201)
14. Petzold A, Keir G, Lim D, Smith M, Thompson EJ. CSF and serum S100B: release and wash-out pattern. Brain Res Bull 2003;61:281-285.
15. Petzold A, Shaw G. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods 2007;319:34-40. (Pubitemid 46107466)
16. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
17. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and A-beta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-1781. (Pubitemid 32881189)
18. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modelling with logistic regression analysis: in search of a sensible strategy in small datasets. Med Decis Making 2001;21:45-56. (Pubitemid 32245030)
19. Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001;300:95-98. (Pubitemid 32162933)
20. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol 2007;6:589-594. (Pubitemid 46921042)
21. Winer JB. Guillain-Barre syndrome. BMJ 2008;337:a671.